Parkin gene therapy for alpha-synucleinopathy: a rat model of Parkinson's disease.

Parkin is known to mitigate alpha-synuclein-induced neuronal cell death in vitro, which suggests that the parkin gene therapy is a candidate for therapeutic strategies for Parkinson's disease (PD). In the present study, the parkin gene therapy was investigated for its ameliorative effects on alpha-synucleinopathy in substantia nigra (SN) of rats. A recombinant adeno-associated viral (rAAV) vector system has frequently been used for the gene transfer to rat SN, and we have previously demonstrated that this technique induced the alpha-synucleinopathy, which closely resembles pathogenetic changes in PD. Therefore, in the present study, the effect of parkin was examined by co-infection of rAAV-parkin with rAAV-alpha-synuclein into dopaminergic neurons in SN. At 13 weeks post-rAAV infection, alpha-synuclein overexpression induced dopaminergic neuron loss, while co-expression of parkin mitigated the alpha-synuclein toxicity. Moreover, alpha-synuclein-induced dopaminergic neuron loss consequently resulted in motor dysfunction, which was also mitigated by parkin. Taken together, our results indicate that the parkin gene therapy is effective against alpha-synucleinopathy, suggesting its potential suitability for patients with PD.

[1]  T. Iwatsubo,et al.  Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  T. Iwatsubo,et al.  Overexpression of α‐synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of α‐synuclein and activation of caspase‐9: resemblance to pathogenetic changes in Parkinson's disease , 2004, Journal of neurochemistry.

[3]  Jian Feng,et al.  Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. , 2004, Human molecular genetics.

[4]  N. Hattori,et al.  Parkin attenuates manganese‐induced dopaminergic cell death , 2004, Journal of neurochemistry.

[5]  B. Ghetti,et al.  Ubiquitination of α-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function* , 2003, Journal of Biological Chemistry.

[6]  T. Dawson,et al.  Molecular Pathways of Neurodegeneration in Parkinson's Disease , 2003, Science.

[7]  N. Hattori,et al.  Parkin Cleaves Intracellular α-Synuclein Inclusions via the Activation of Calpain* , 2003, Journal of Biological Chemistry.

[8]  J. Feldon,et al.  Dopamine-dependent neurodegeneration in rats induced by viral vector-mediated overexpression of the parkin target protein, CDCrel-1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Clay W Scott,et al.  Parkin suppresses wild-type α-synuclein-induced toxicity in SHSY-5Y cells , 2003 .

[10]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[11]  Makoto Hashimoto,et al.  Transgenic Models of α‐Synuclein Pathology , 2003 .

[12]  Isao Nishimura,et al.  Parkin Suppresses Dopaminergic Neuron-Selective Neurotoxicity Induced by Pael-R in Drosophila , 2003, Neuron.

[13]  A. Abeliovich,et al.  Parkin Is a Component of an SCF-like Ubiquitin Ligase Complex and Protects Postmitotic Neurons from Kainate Excitotoxicity , 2003, Neuron.

[14]  E. Hirsch,et al.  Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. , 2003, Human molecular genetics.

[15]  A. Björklund,et al.  Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: A new primate model of Parkinson's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  P. Lockhart,et al.  Parkin Protects against the Toxicity Associated with Mutant α-Synuclein Proteasome Dysfunction Selectively Affects Catecholaminergic Neurons , 2002, Neuron.

[17]  J. Trojanowski,et al.  Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions* , 2002, The Journal of Biological Chemistry.

[18]  P. Aebischer,et al.  α-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  B. Hyman,et al.  Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. , 2002, The American journal of pathology.

[20]  A. Björklund,et al.  Parkinson-Like Neurodegeneration Induced by Targeted Overexpression of α-Synuclein in the Nigrostriatal System , 2002, The Journal of Neuroscience.

[21]  Ronald L Klein,et al.  Dopaminergic cell loss induced by human A30P alpha-synuclein gene transfer to the rat substantia nigra. , 2002, Human gene therapy.

[22]  C. Ross,et al.  Parkin ubiquitinates the α-synuclein–interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease , 2001, Nature Medicine.

[23]  L. Petrucelli,et al.  Co-association of parkin and α-synuclein , 2001 .

[24]  N. Hattori,et al.  An Unfolded Putative Transmembrane Polypeptide, which Can Lead to Endoplasmic Reticulum Stress, Is a Substrate of Parkin , 2001, Cell.

[25]  Nobutaka Hattori,et al.  Ubiquitination of a New Form of α-Synuclein by Parkin from Human Brain: Implications for Parkinson's Disease , 2001, Science.

[26]  H. Büeler,et al.  Recombinant AAV vectors containing the foot and mouth disease virus 2A sequence confer efficient bicistronic gene expression in cultured cells and rat substantia nigra neurons , 2001, Gene Therapy.

[27]  C. Ross,et al.  Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. , 2001, Human molecular genetics.

[28]  A. Parent,et al.  Parkin immunoreactivity in the brain of human and non‐human primates: An immunohistochemical analysis in normal conditions and in Parkinsonian syndromes , 2001, The Journal of comparative neurology.

[29]  A. Brice,et al.  Alpha-synuclein and Parkinson's disease , 2000, Cellular and Molecular Life Sciences CMLS.

[30]  T. Dawson,et al.  Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Y. Imai,et al.  Parkin Suppresses Unfolded Protein Stress-induced Cell Death through Its E3 Ubiquitin-protein Ligase Activity* , 2000, The Journal of Biological Chemistry.

[32]  E. Masliah,et al.  α-Synuclein Promotes Mitochondrial Deficit and Oxidative Stress , 2000 .

[33]  Shinsei Minoshima,et al.  Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase , 2000, Nature Genetics.

[34]  H. Mizuguchi,et al.  IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  P J McLean,et al.  Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. , 2000, The Journal of biological chemistry.

[36]  P. Lansbury,et al.  Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[37]  S. Minoshima,et al.  Immunohistochemical and subcellular localization of parkin protein: Absence of protein in autosomal recessive juvenile parkinsonism patients , 1999, Annals of neurology.

[38]  Peter T. Lansbury,et al.  Accelerated in vitro fibril formation by a mutant α-synuclein linked to early-onset Parkinson disease , 1998, Nature Medicine.

[39]  A. Jonas,et al.  Stabilization of α-Synuclein Secondary Structure upon Binding to Synthetic Membranes* , 1998, The Journal of Biological Chemistry.

[40]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[41]  I. Pastan,et al.  Co-expression of human adenosine deaminase and multidrug resistance using a bicistronic retroviral vector. , 1998, Human gene therapy.

[42]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[43]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[44]  J. P. Huston,et al.  The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments , 1996, Progress in Neurobiology.

[45]  S. Tsuji,et al.  Familial juvenile parkinsonism , 1994, Neurology.

[46]  U. Ungerstedt,et al.  Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. , 1970, Brain research.

[47]  A. Schapira,et al.  Genetic and environmental factors in the cause of Parkinson's disease , 2003, Annals of neurology.

[48]  S. Hunot,et al.  Neuroinflammatory processes in Parkinson's disease , 2003, Annals of neurology.